EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

AXL – a new player in resistance to HER2 blockade

Anna Adam-Artigues, Enrique J Arenas, Joaquín Arribas, Aleix Prat, Juan Miguel Cejalvo

Cancer Treatment Reviews · 2023

DOI: 10.1016/j.ctrv.2023.102639 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2023. Verfasst von Anna Adam-Artigues und 4 weiteren Autor:innen. Beteiligte Einrichtung: INCLIVA Biomedical Research Institute, Spain. Electronic address: anar4@alumni.uv.es. Hauptthemen laut MEDLINE: Axl Receptor Tyrosine Kinase, Breast Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Axl Receptor Tyrosine KinaseBreast NeoplasmsFemaleHumansCell Line, TumorDrug Resistance, NeoplasmProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinases

Stichwörter der Autor:innen

AXLCancerHER2 diseaseResistance

Substanzen

Axl Receptor Tyrosine KinaseProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAXL protein, human

Autor:innen und Institutionen

  • INCLIVA Biomedical Research Institute, Spain. Electronic address: anar4@alumni.uv.es.
  • Josep Carreras Leukaemia Research Institute, Spain; Center for Biomedical Network Research on Cancer (CIBERONC), Spain. Electronic address: earenas@vhio.net.
  • Center for Biomedical Network Research on Cancer (CIBERONC), Spain; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Insti…
  • August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain; SOLTI Breast Cancer Research Group, Spain. Electronic address: ALPRAT@clinic.cat.
  • INCLIVA Biomedical Research Institute, Spain; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Spain; Department of Medical Oncology, Hospital Clínico Universitario de València, Spain. Electroni…

Zitieren

APA

Adam-Artigues, A., Arenas, E. J., Arribas, J., Prat, A., & Cejalvo, J. M. (2023). AXL – a new player in resistance to HER2 blockade. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2023.102639

Vancouver

Adam-Artigues A, Arenas EJ, Arribas J, Prat A, Cejalvo JM. AXL – a new player in resistance to HER2 blockade. Cancer Treatment Reviews. 2023. doi:10.1016/j.ctrv.2023.102639

BibTeX
@article{AdamArtigues2023,
  author = {Adam-Artigues, Anna and Arenas, Enrique J and Arribas, Joaquín and Prat, Aleix and Cejalvo, Juan Miguel},
  title = {AXL – a new player in resistance to HER2 blockade},
  journal = {Cancer Treatment Reviews},
  year = {2023},
  doi = {10.1016/j.ctrv.2023.102639}
}
Kostenlos starten →